Dendritic cell-based approaches to cancer immunotherapy

Bibliography

• DARROW T, SLINGLUFF C, SEIGLER H: The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J. Immunol (1989) 42:3329–3335.
   Google Scholar
• THOMPSON JA, GRUNER TF, ZIMMERMANN W: Carci-noembryonic antigen gene family: molecular biology and clinical prospectives. j Clin. Lab. Anal. (1991) 5:344–366.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN PC, TRAVERSARI C, CHOMEZ P et al.:A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (1991) 254:1643–1647.
   Google Scholar
• DISIS ML, CHEEVER MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. (1997) 71:343–371.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Cloning of the gene coding for a shared human melanoma anti-gen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA (1994) 91:3515–3519.
   PubMed Web of Science ®Google Scholar
• BARND DL, LAN MS, METZGAR RS, FINN OJ: Specific MHC-unrestricted recognition of tumor associated mucins by human cytotoxic cells. Proc. Natl. Acad. Sci. USA (1989) 86:7159–7163.
   PubMed Web of Science ®Google Scholar
• BOS JL: ras Oncogenes in human cancer: a review. Cancer Res. (1989) 49:4682.
   PubMed Web of Science ®Google Scholar
• HALBERT C, DEMERS GW, GALLOWAY DA: The E7 gene of human papillomavirus type 16 is sufficient for im-mortalization of human epithelial cells. J. Virol. (1991) 65:473–478.
   PubMed Web of Science ®Google Scholar
• DISIS ML, CALENOFF E, MCLAUGHLIN G et al.: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. (1994) 54:16–20.
   PubMed Web of Science ®Google Scholar
• FISK B, BLEVINS TL, WHARTON JT, IOANNIDES CG: Iden-tification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. (1995) 181:2109–2117.
   PubMed Web of Science ®Google Scholar
• TSANG KY, ZAREMBA S, NIERODA CA et al.: Generationof human cytotoxic T cells specific for human carci-noembryonic antigen epitopes from patients immu-nized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. (1995) 87:982–990.
   PubMed Web of Science ®Google Scholar
• VAN DEN EYNDE B, HAINUT P, HERIN M et al.: Presence on a human melanoma of multiple antigens recog-nized by autologous CTL. Int. J. Cancer (1989) 44:634–640.
   Google Scholar
• COULIE PG, SOMVILLE M, LEHMANN F et al.: Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Can-cer (1992) 50:289–297.
   PubMed Web of Science ®Google Scholar
• MAZZOCCHI A, BELLI F, MASCHERONI L et al.: Frequency of cytotoxic T lymphocyte precursors (CTLp) interact-ing with autologous tumor via the T-cell receptor: lim-iting dilution analysis of specific CTLp in peripheral blood and tumor invaded lymph nodes of melanoma patients. Int. J. Cancer (1994) 58:330–339.
   PubMed Web of Science ®Google Scholar
• GILBOA E, LYERLY HK: Specific active immunotherapy of cancer using genetically modified tumor vaccines. Ther. Cancer Updates (1994) 4:1–16.
   Google Scholar
• MCANENY D, RYAN CA, BEAZLEY RM, KAUFMAN HL: Re-sults of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol (1996) 3:495–500.
   PubMed Web of Science ®Google Scholar
• CONRY RM, LOBUGLIO AF, MOORE SE et al.: A carci-noembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. (1995) 2:59–65.
   PubMed Web of Science ®Google Scholar
• HUANG AYC, GOLUMBEK P, AHMADZEDAH M et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 264:961–965.
   PubMed Web of Science ®Google Scholar
• GROUARD G, DURAND I, FILGUEIRA L et al.: Dendritic cells capable of stimulating T cells in germinal centers. Nature (1996) 384:364–367.
   PubMed Web of Science ®Google Scholar
• GROUARD G, RISSOAN MC, FILGUIERA L et al: The enig-matic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. (1997) 185:1101–1111.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• ZHOU L-J, TEDDER TF: Human blood dendritic cells se-lectively express CD83, a member of the immuno-globulin superfamily. j Immunol (1995) 154:3821–3835.
   PubMed Web of Science ®Google Scholar
• HOCK BD, STARLING GC, DANIEL PB, HART DNJ: CMRF-44, a novel monoclonal antibody to an activation anti-gen expressed by the allostimulatory cells within pe-ripheral blood, including dendritic cells. Immunol (1994) 83:573–581.
   PubMed Web of Science ®Google Scholar
• SUSS G, SHORTMAN K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. (1996) 183:1789–1796.
   PubMed Web of Science ®Google Scholar
• LIU YJ, GROUARD G, DE BOUTTEILLIER O, BANCHEREAU J: Follicular dendritic cells and germinal centers. Int. Rev. Cytol (1996) 166:139–179.
   PubMed Web of Science ®Google Scholar
• MCKINNEY EC, STREILEIN EW: On the extraordinary ca-pacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo. J. Immunol. (1989) 143:1560–1564.
   PubMed Web of Science ®Google Scholar
• MACATONIA SE, TAYLOR PM, KNIGHT SC, ASKONAS BA:Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. (1988) 169:1255–12.
   Web of Science ®Google Scholar
• NAIR S, ZHOU F, REDDY R, HUANG L, ROUSE BT: Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte re-sponses in vitro. J. Exp. Med. (1992) 175:609–612.
   PubMed Web of Science ®Google Scholar
• MEHTA-DAMANI A, MARKOWICZ S, ENGLEMAN EG: Gen-eration of antigen-specific CD8+ CTLs from naive pre-cursors. J. Immunol (1994) 153:996–1003.
   PubMedGoogle Scholar
• TAKAHASHI H, NAKAGAWA Y, YOKOMURO K, BERZOF-SKY JA: Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated 11IV-1 enve-lope derived peptide-pulsed dendritic cells. Int. Immu-nol. (1993) 5:849–857.
   PubMed Web of Science ®Google Scholar
• NAIR S, BABU JS, DUNHAM RG et al.: Induction of pri-mary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Vim]. (1993) 67:4062–4069.
   Web of Science ®Google Scholar
• ROUSE RJD, NAIR SK, LYDY SL etal: Induction in vitro of primary cytotoxic T-lymphocytes responses with DNA encoding herpes simplex virus proteins. J. Vint]. (1994) 68:5685–5689.
   Google Scholar
• FLAMAND V, SORNASSE T, THIELEMANS K et al.: Murinedendritic cells pulsed in vitro with tumor antigen in-duce tumor resistance in vivo. Eur. j Immunol. (1994) 24:605–610.
   PubMed Web of Science ®Google Scholar
• PAGLIA P, CHIODONI C, RODOLFO M, COLOMBO MP: Murine dendritic cells loaded in vitro with soluble pro-tein prime cytotoxic T lymphocytes against tumor an-tigen in vivo. J. Exp. Med. (1996) 183:317–322.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, SNYDER D, GILBOA E: Induction of anti-tumor immunity using bone marrow-generated den-dritic cells. J. Immunol. (1996) 156:2918–2926.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, GILBOA E: Bone marrow-generated den-dritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. (1995) 182:255–260.
   PubMed Web of Science ®Google Scholar
• OSSEVOORT MA, FELTKAMP MCW, VAN VEEN KJH et al.: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protec-tion against a human papillomavirus type 16-induced tumor. J. Immunother. (1995) 18:86–94.
   Google Scholar
• MAYORDOMO JI, ZORINA T, STORKUS WJ et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nature Med. (1995) 12:1297–13.
   Web of Science ®Google Scholar
• CELLUZZI CM, MAYORDOMO JI, STORKUS WJ, LOTZE MT, FALO JLD: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor im-munity. J. Exp. Med. (1996) 183:283–287.
   PubMed Web of Science ®Google Scholar
• HSU FJ, BENIKE C, FAGNONI F et al.: Vaccination of pa-tients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. (1996) 2:52–.
   PubMed Web of Science ®Google Scholar
• •One of the first reported clinical studies of immunisations with dendritic cells.
   Google Scholar
• VALONE FH, SMALL EJ, WHISENANT S et al.: Immuno-therapy of hormone refractory prostate cancer with antigen-pulsed dendritic cells: a Phase I/II study. Proc. Am. Soc. Clin. Oncol (1998) 17:346a.
   Google Scholar
• YOUNG J, STEINMAN R: Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mito-gens, as studied with a new technique for enriching blood dendritic cells. Cell. Immunol. (1988) 111:167–182.
   PubMed Web of Science ®Google Scholar
• KNIGHT SC, FARRANT J, BRYANT A et al: Non-adherent, low-density cells from human peripheral blood con-tain dendritic cells and monocytes, both with veiled morphology. Immunol (1986) 57:595–603.
   PubMed Web of Science ®Google Scholar
• WILLIAMS LA, EGNER W, HART DNJ: Isolation and func-tion of human dendritic cells. Int. Rev. Cytol. (1994) 153:41–103.
   PubMed Web of Science ®Google Scholar
• THOMAS R, DAVIS L, LIPSKY P: Isolation and characteri-zation of human peripheral blood dendritic cells. J. Im-munol. (1993) 150:821–834.
   PubMed Web of Science ®Google Scholar
• VAN VOORHIS W, HAIR L, STEINMAN R et al.: Human dendritic cells: enrichment and characterization from peripheral blood. J. Exp. Med. (1982) 155:1172–1187.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, CIERNIK IF, CARBONE DP: Dendritic cells in antitumor immune responses. I. Defective anti-gen presentation in tumor-bearing hosts. Cell. Immu-nol. (1996) 170:101–110.
   Google Scholar
• GABRILOVICH DI, NADAF S, CORAK J et al.: Dendritic cells in antitumor immune responses. II Dendritic cells grown from bone marrow precursors, but not mature DC from tumor bearing mice, are effective anti-gen carriers in the therapy of established tumors. Cell. Immunol. (1996) 170:111–119.
   Google Scholar
• CAUX C, VANDERVLIET B, MASSACRIER C et al.: CD34+hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNEcc. J. Exp. Med. (1996) 184:695–706.
   PubMed Web of Science ®Google Scholar
• SZABOLCS P, AVIGAN D, GEZELTER S et al.: Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony forming unit intermediate. Blood (1996) 87:4520–30.
   PubMed Web of Science ®Google Scholar
• SANTIAGO-SCHWARZ F, BELILOS E, DIAMOND B et al.: TNF in combination with GM-CSF enhances the differ-entiation of neonatal cord blood stem cells into den-dritic cells and macrophages. J. Leuk. Biol. (1992) 52:274–281.
   PubMed Web of Science ®Google Scholar
• REID CDL, STACKPOOLE A, MEAGER A et al: Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cyto-kines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J. Immunol (1992) 149:2681–2688.
   PubMed Web of Science ®Google Scholar
• SZABOLCS P, MOORE MAS, YOUNG JW: Expansion of immunostimulatory dendritic cells among the mye-loid progeny of human CD34+ bone marrow precur- sorsculturedwithc-kitligand, granulocyte-macrophage colony-stimulating factor, and TNF-a. J. Immunol (1995) 154:5851–5861.
   PubMed Web of Science ®Google Scholar
• SIENA S, DI NICOLA M, BREGNI M et al: Massive ex vivo generation of functional dendritic cells from mobi-lized CD34+ blood progenitors for anti-cancer ther-apy. Exp. Hematol. (1995) 23:1463–1471.
   PubMed Web of Science ®Google Scholar
• ZHOU L-J, TEDDER TF: CD14+ Blood monocytes can dif-ferentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA (1996) 93:2588–2592.
   PubMed Web of Science ®Google Scholar
• ROMANI N, GRUNER S, BRANG D et al.: Proliferating den-dritic cell progenitors in human blood. J. Exp. Med. (1994) 180:83–93.
   PubMed Web of Science ®Google Scholar
• BENDER A, SAPP M, SCHULER G et al.: Improved meth-ods for the generation of dendritic cells from nonpro-liferating progenitors in human blood. J. Immunol. Methods (1996) 196:121–135.
   PubMed Web of Science ®Google Scholar
• ROMANI N, REIDER D, HEUER M et al.: Generation of ma-ture dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods (1996) 196:137–141.
   PubMed Web of Science ®Google Scholar
• •This paper reports useful methods for generating dendritic cells for clinical studies and also addresses questions about the maturity of dendritic cells generated with GM-CSF and IL-4 alone.
   Google Scholar
• MORSE MA, ZHOU L-J, TEDDER TF et al.: Generation of dendritic cells in vitro from peripheral blood mono-nuclear cells with GM-CSF, IL-4, and TNF-a for use in cancer immunotherapy. Ann Surg (1997) 226:6–16.
   PubMed Web of Science ®Google Scholar
• MORTARINI R, ANICHINI A, DI NICOLA M et al.: Autolo-gous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-A/Mart-127_35-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res. (1997) 57:5534–5541.
   Google Scholar
• ••A well-performed study that attempts to compare theantigen-stimulatory activity of dendritic cells generated by the two major methods.
   Google Scholar
• WONG C, MORSE M, NAIR SK: Induction of primary, hu-man antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immuno-ther. (1998) 21:32–40.
   PubMed Web of Science ®Google Scholar
• CAUX C, MASSACRIER C, VANBERVLIET B et al.: Activa-tion of human dendritic cells through CD40 cross-linking. J. Exp. Med. (1994) 180:1263–1272.
   PubMed Web of Science ®Google Scholar
• MORSE MA, LYERLY HK, GILBOA E, THOMAS EK, NAIR SK: Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. (1998). (In Press.)
   Google Scholar
• LEVINE TP, CHAIN BM et al.: Endocytosis by antigen pre-senting cells: dendritic cells are as endocytically active as other antigen presenting cells. Proc. Natl. Acad. Sci. USA (1992) 89:8342–8346.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, CELLA M, DANIELI C, LANZAVECCHIA A:Dendritic cells use macropinocytosis and the man-nose receptor to concentrate macromolecules in the major histocompatibility complex II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. (1995) 182:389–400.
   PubMed Web of Science ®Google Scholar
• REIS E, SOUSA C, STAHL PD, AUSTIN JM: Phagocytosis ofantigens by Langerhans cells in vitro. J. Exp. Med. (1993) 178:509–519.
   PubMed Web of Science ®Google Scholar
• SCHEICHER C, MEHLIG M, DIENES H-P, RESKE K: Uptake of microparticle-absorbed protein antigen by bone marrow derived dendritic cells results in upregulation of interleukin la and interleukin 12 p40/p35 and trig-gers prolonged, efficient antigen presentation. Eur. J. Immunol. (1995) 25:1566–1577.
   PubMed Web of Science ®Google Scholar
• GUERY J-C, ADORINI: Dendritic cells are the most effi-cient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J. Immunol (1995) 154:536–544.
   PubMed Web of Science ®Google Scholar
• LEHNER PJ, CRESSWELL P: Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol. (1996) 8:59–67.
   PubMed Web of Science ®Google Scholar
• NAIR SK, SNYDER D, ROUSE BT, GILBOA E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Can-cer (1997) 70:706–715.
   PubMed Web of Science ®Google Scholar
• BOCZKOWSKI D, NAIR S, SNYDER D, GILBOA E: Den-dritic cells pulsed with RNA are potent antigen pre-senting cells in vitro and in vivo. J. Exp. Med. (1996) 184:465–472.
   PubMed Web of Science ®Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE MA et al.: Induction ofprimary carcinoembryonic antigen (CEA) -specific cy-totoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotech. (1998) 16:364–369.
   PubMed Web of Science ®Google Scholar
• BHARDWAJ N, BENDER A, GONZALEZ N et al.: Influenza virus-infected dendritic cells stimulate strong prolif-erative and cytolytic responses from human CD8+ T cells. J. Clin. Invest. (1994) 94:797–807.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. (1998) 4:328–332.
   PubMed Web of Science ®Google Scholar
• GONG J, CHEN D, KASHIWABA M, KUFE D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. (1997) 3:558–561.
   PubMed Web of Science ®Google Scholar
• RUFF AL, GUARNIERI FG, STAVELEY-OVARROLL K et al: The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the ly-sosome membrane protein trafficking pathway. J. Biol. Chem. (1997) 272:8671–8678.
   PubMed Web of Science ®Google Scholar
• GREENBERG PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimina-tion of tumor cells. Adv. Immunol (1991) 49:281–355.
   PubMed Web of Science ®Google Scholar
• HARNAOKA T, FUJIWARA H: Phenotypically and func-tionally distinct T cell subsets in anti-tumor responses. Immunol. Today (1987) 8:267–269.
   PubMedGoogle Scholar
• ZITVOGEL L, MAYORDOMO JI, TJANDRAWAN T et al: Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Thl-asssociated cytokines. J. Exp. Med. (1996) 183:87–97.
   PubMed Web of Science ®Google Scholar
• NAIR SK, BOCZKOWSKI D, SNYDER D, GILBOA E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. j Immunol. (1997) 27:589–597.
   PubMed Web of Science ®Google Scholar
• ANICHINI A, MORTARINI R, MACCALLI C et al.: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Imrnunol. (1996) 156:208–217.
   Google Scholar
• •This study indicates that the currently identified tumour anti-gens may not be the authentic tumour rejection antigens and that these antigens may even vary from patient to patient.
   Google Scholar
• MUKHERJI B, CHAKRABORTY NG, YAMASAKI S et al.: In-duction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. NatI Acad. ScL USA (1995) 92:8078–8082.
   PubMed Web of Science ®Google Scholar
• REICHARDT V, OKADA C, BENIKE et al.: Idiotypic vacci-nation using dendritic cells for multiple myeloma pa-tients after autologous peripheral blood stem cell transplantation. Blood (1996) 88:481. (Abstract.)
   Google Scholar
• MURPHY G, TJOA B, RAGDE H et al.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific pep-tides from prostate-specific membrane antigen. The Prostate (1996) 29:371–380.
   PubMed Web of Science ®Google Scholar
• HINKLE A, GITLITZ B, MUKDERS P et al.: Dendritic cell therapy for metastatic renal cell carcinoma-A transla-tional Phase I clinical trial. Proc. Am. Soc. Olin. Oncol (1998) 17:432a.
   Google Scholar
• MARASKOVSKY E, BRASEL K, TEEPE M et al: Dramatic in-crease in the number of functionally mature dendritic cells in F1t3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. (1996) 184:1953–1962.
   PubMed Web of Science ®Google Scholar
• ZITVOGEL L, REGNAULT A, LOZIER A, WOLFERS J et al.:Eradication of established murine tumors using a novel cell-free vaccine; dendritic cell-derived exo-somes. (1998) Nature Merl. 4: 594–600.
   Google Scholar